Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP trimmed its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 73.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 96,294 shares of the biotechnology company’s stock after selling 264,455 shares during the period. Wellington Management Group LLP’s holdings in Arcturus Therapeutics were worth $2,235,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Sumitomo Mitsui Trust Group Inc. increased its stake in Arcturus Therapeutics by 45.6% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,275,715 shares of the biotechnology company’s stock valued at $52,819,000 after purchasing an additional 712,650 shares during the last quarter. Empire Life Investments Inc. purchased a new stake in Arcturus Therapeutics in the 3rd quarter valued at about $3,498,000. XTX Topco Ltd acquired a new position in shares of Arcturus Therapeutics during the 2nd quarter valued at about $596,000. Squarepoint Ops LLC purchased a new position in shares of Arcturus Therapeutics during the 2nd quarter worth about $718,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Arcturus Therapeutics in the third quarter worth approximately $191,000. 94.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ARCT. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday. HC Wainwright restated a “buy” rating and set a $63.00 price objective on shares of Arcturus Therapeutics in a report on Tuesday. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $66.75.

Arcturus Therapeutics Stock Down 5.8 %

Shares of ARCT stock opened at $14.82 on Thursday. Arcturus Therapeutics Holdings Inc. has a fifty-two week low of $14.35 and a fifty-two week high of $45.00. The firm’s 50 day moving average price is $18.48 and its two-hundred day moving average price is $21.84. The stock has a market cap of $401.43 million, a price-to-earnings ratio of -6.68 and a beta of 2.62.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.44. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The firm had revenue of $41.67 million during the quarter, compared to analysts’ expectations of $49.16 million. During the same period in the prior year, the company earned ($0.61) EPS. On average, equities analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.31 EPS for the current fiscal year.

Insider Activity

In other Arcturus Therapeutics news, COO Pad Chivukula sold 12,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total value of $249,120.00. Following the completion of the transaction, the chief operating officer now owns 435,334 shares in the company, valued at $9,037,533.84. This represents a 2.68 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 15.30% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.